Skip to main content
. 2016 Sep 22;6(2):634–646. doi: 10.5966/sctm.2016-0071

Figure 3.

Figure 3

Motor coordination performance after hMSC CM (i.e., secretome) injection into the substantia nigra and striatum. (A): Latency to fall was measured in the accelerating RotaRod test, demonstrating that the hMSC CM‐injected animals had a significant improvement (at 1 and 4 weeks after injection; p < .05) in their motor coordination when compared with the 6‐OHDA group 6‐OHDA. (B): Paw‐reaching performance (assessed by the staircase test) also demonstrated a significant improvement (at 4 and 7 weeks after injection; p < .05) of the forelimb coordination of the hMSC CM‐injected animals when compared with the 6‐OHDA group. Even when the animals were submitted to a paw‐reaching forced‐performance task, the hMSC CM‐injected animals presented a better performance on the affected side (at 4 and 7 weeks after injection; p < .05) when compared with the 6‐OHDA group (C, D). For the RotaRod test, the numbers tested in the sham, 6‐OHDA, and hMSC CM groups were 9, 9, and 8, respectively. For staircase test, the numbers tested in the sham, 6‐OHDA, and hMSC CM groups were 10, 10, and 11, respectively. Data are presented as mean ± SEM. ∗, p < .05; #, sham animals statistically different from 6‐OHDA‐ and hMSC CM‐injected animals, p < .001. Abbreviations: hMSC CM, human mesenchymal stem cell‐conditioned medium; 6‐OHDA, 6‐hydroxidopamine; sec, seconds; w, weeks.